MARCHIO', Caterina
 Distribuzione geografica
Continente #
NA - Nord America 5983
EU - Europa 3532
AS - Asia 1670
SA - Sud America 50
AF - Africa 44
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 5
Totale 11313
Nazione #
US - Stati Uniti d'America 5865
IT - Italia 1121
CN - Cina 1060
IE - Irlanda 532
SE - Svezia 370
FR - Francia 247
DE - Germania 226
AT - Austria 196
UA - Ucraina 178
VN - Vietnam 174
FI - Finlandia 164
GB - Regno Unito 127
PL - Polonia 117
KR - Corea 116
JP - Giappone 114
CA - Canada 100
IN - India 63
NL - Olanda 58
HK - Hong Kong 47
ES - Italia 33
AU - Australia 27
BR - Brasile 27
SN - Senegal 27
CH - Svizzera 23
BE - Belgio 22
RO - Romania 22
TR - Turchia 19
RU - Federazione Russa 18
PT - Portogallo 17
NO - Norvegia 16
TW - Taiwan 16
MX - Messico 15
GR - Grecia 12
CL - Cile 11
IR - Iran 10
DK - Danimarca 8
UZ - Uzbekistan 7
HU - Ungheria 6
CZ - Repubblica Ceca 5
ID - Indonesia 5
PK - Pakistan 5
QA - Qatar 5
TH - Thailandia 5
CO - Colombia 4
EG - Egitto 4
EU - Europa 4
MY - Malesia 4
PH - Filippine 4
SA - Arabia Saudita 4
SG - Singapore 4
ZA - Sudafrica 4
BA - Bosnia-Erzegovina 3
SI - Slovenia 3
AE - Emirati Arabi Uniti 2
AR - Argentina 2
BM - Bermuda 2
BW - Botswana 2
IS - Islanda 2
JO - Giordania 2
KE - Kenya 2
NZ - Nuova Zelanda 2
PE - Perù 2
SD - Sudan 2
A1 - ???statistics.table.value.countryCode.A1??? 1
BO - Bolivia 1
EC - Ecuador 1
EE - Estonia 1
GE - Georgia 1
HR - Croazia 1
IL - Israele 1
IQ - Iraq 1
LT - Lituania 1
LU - Lussemburgo 1
PS - Palestinian Territory 1
PY - Paraguay 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TN - Tunisia 1
TZ - Tanzania 1
VE - Venezuela 1
Totale 11313
Città #
Fairfield 716
Chandler 636
Dublin 528
Beijing 512
Houston 471
Ann Arbor 413
Torino 390
Woodbridge 365
Ashburn 313
Wilmington 264
Seattle 243
Cambridge 208
Vienna 189
Pisa 187
Villeurbanne 171
Jacksonville 158
Medford 156
Princeton 156
Dearborn 140
Redwood City 137
Nyköping 123
Warsaw 112
Dong Ket 93
New York 79
Shanghai 62
San Diego 56
Hangzhou 55
Boston 54
Guangzhou 51
Nanjing 49
Fremont 39
Toronto 39
Milan 37
Boardman 36
Hefei 28
Norwalk 28
Tokyo 27
Ottawa 26
Phoenix 25
Turin 25
Chengdu 24
Falls Church 24
London 18
Silver Spring 18
Chicago 17
Jinan 15
Wuhan 15
Central District 14
Changsha 14
Hebei 14
Pittsburgh 14
Rome 14
Brussels 13
Fuzhou 13
Seoul 13
Kunming 12
Mountain View 12
Chongqing 11
Tianjin 11
Columbus 10
Paris 10
Redmond 10
Xian 10
Carrara 9
Hanover 9
Nagoya 9
Santiago 9
Taipei 9
Verona 9
Zhengzhou 9
Auburn Hills 8
Bologna 8
Lexington 8
Mumbai 8
Nanchang 8
Napoli 8
Philadelphia 8
San Francisco 8
Buffalo 7
Dallas 7
Fosses 7
Hamilton 7
Madrid 7
Moncalieri 7
Munich 7
Ningbo 7
Shenyang 7
Basel 6
Berlin 6
Charlestown 6
Evanston 6
Guiyang 6
Hyderabad 6
Montréal 6
Muenster 6
Renton 6
San Mateo 6
Varese 6
Amsterdam 5
Düsseldorf 5
Totale 7989
Nome #
Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands 602
Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors 293
BCAM and LAMA5 Mediate the Recognition between Tumor Cells and the Endothelium in the Metastatic Spreading of KRAS Mutant Colorectal Cancer 242
Acid-free glyoxal as a substitute of formalin for structural and molecular preservation in tissue samples 233
Molecular evidence in support of the neoplastic and precursor nature of microglandular adenosis. 232
Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies. 214
Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast 212
SF3B1mutations constitute a novel therapeutic target in breast cancer 208
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast 192
A comprehensive PDX gastric cancer collection captures cancer cell intrinsic transcriptional MSI traits 178
Distinctive pathological and clinical features of lung carcinoids with high proliferation index 170
High-throughput molecular analysis from leftover of fine needle aspiration cytology of mammographically detected breast cancer. 168
The expression of growth hormone releasing hormone (GHRH) and its receptors in breast carcinomas with apocrine differentiation - further evidence of the presence of a GHRH pathway in these tumors 150
miR-221/222 control luminal breast cancer tumor progression by regulating different targets 144
Differences and homologies of chromosomal alterations within and between breast cancer cell lines: a clustering analysis 143
Awareness of mutational artefacts in suboptimal DNA samples: possible risk for therapeutic choices 141
Effect of low doses of estradiol and tamoxifen on breast cancer cell karyotypes 140
Genetic analysis of microglandular adenosis and acinic cell carcinomas of the breast provides evidence for the existence of a low-grade triple-negative breast neoplasia family 139
Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers 139
Spontaneous and pronase-induced HER2 truncation increases the trastuzumab binding capacity of breast cancer tissues and cell lines. 137
Pleomorphism of the Nuclear Envelope in breast cancer: a new approach to an old problem 136
Critical roles of specimen type and temperature before and during fixation in the detection of phosphoproteins in breast cancer tissues 135
Revisiting the technical validation of tumour biomarker assays: how to open a Pandora's box 133
The perfect pathology report after neoadjuvant therapy 133
A collection of primary tissue cultures of tumors from vacuum packed and cooled surgical specimens: a feasibility study 132
Current Challenges for HER2 Testing in Diagnostic Pathology: State of the Art and Controversial Issues 127
Pathological non-response to chemotherapy in a neoadjuvant setting of breast cancer: an inter-institutional study 125
Classification of pulmonary neuroendocrine tumors: New insights 123
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond 122
“To Be or Not to Be in a Good Shape”: Diagnostic and Clinical Value of Nuclear Shape Irregularities in Thyroid and Breast Cancer 120
Tissue arrays as fiducial markers for section alignment in 3-D reconstruction technology 120
The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment 120
THE EXPRESSION OF LINE1-MET CHIMERIC TRANSCRIPT IDENTIFIES A SUBGROUP OF AGGRESSIVE BREAST CANCERS 118
The impact of malignant nipple discharge cytology (NDc) in surgical management of breast cancer patients 116
PAX8–GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid 115
Mitotic Spindle Assembly and Genomic Stability in Breast Cancer Require PI3K-C2α Scaffolding Function 114
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants 113
Micropapillary ductal carcinoma in situ of the breast: an inter-institutional study 112
Unraveling the chromosome 17 patterns of FISH in interphase nuclei: an in-depth analysis of the HER2 amplicon and chromosome 17 centromere by karyotyping, FISH and M-FISH in breast cancer cells. 111
Search for Neuro-Endocrine Markers (Chromogranin A, Synaptophysin and VGF) in Breast Cancers. An integrated Approach Using Immunohistochemistry and Gene Expression Profiling 110
Extreme assay sensitivity in molecular diagnostics further unveils intratumour heterogeneity in metastatic colorectal cancer as well as artifactual low-frequency mutations in the KRAS gene 107
Quantification of HER2 and estrogen receptor heterogeneity in breast cancer by single-molecule RNA fluorescence in situ hybridization 103
HER2 in Breast Cancer 99
CUTseq is a versatile method for preparing multiplexed DNA sequencing libraries from low-input samples 94
Massively parallel sequencing of phyllodes tumours of the breast reveals actionable mutations, and TERT promoter hotspot mutations and TERT gene amplification as likely drivers of progression 91
Assessment of a High Sensitivity Method for Identification of IDH1 R132x Mutations in Tumors and Plasma of Intrahepatic Cholangiocarcinoma Patients 91
Small-cell carcinoma of the breast with squamous differentiation 90
CXCL12 expression is a bona fide predictor of recurrence in lung neuroendocrine tumours; a multicentric study with emphasis on atypical carcinoids - a short report 86
The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study 85
Personalized therapeutic strategies in HER2-driven gastric cancer 85
The Multifaceted Nature of Tumor Microenvironment in Breast Carcinomas 79
Next-Generation Sequencing in Clinical Practice: Is It a Cost-Saving Alternative to a Single-Gene Testing Approach? 78
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplification 75
Rediscovering secondary tumors of the prostate in the molecular era 75
The genetic landscape of breast carcinomas with neuroendocrine differentiation 75
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study 74
ESR1 mutations in metastatic lobular breast cancer patients 73
RollFISH achieves robust quantification of single-molecule RNA biomarkers in paraffin-embedded tumor tissue samples 72
Traditional urinary cytology and tyrosinase RT-PCR in metastatic melanoma patients: correlation with clinical status 70
Predictive Diagnostic Pathology in the Target Therapy Era in Breast Cancer 69
Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast 69
Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor 69
Pathology and Molecular Pathology of Breast Cancer 69
Caveolin 1 expression favors tumor growth and is associated with poor survival in primary lung adenocarcinomas 69
Breast cancer precursors revisited: molecular features and progression pathways. 68
Breast carcinomas with low amplified/equivocal HER2 by Ish: Potential supporting role of multiplex ligation-dependent probe amplification 65
Cold Formalin Fixation Guarantees DNA Integrity in Formalin Fixed Paraffin Embedded Tissues: Premises for a Better Quality of Diagnostic and Experimental Pathology With a Specific Impact on Breast Cancer 65
Identification of TENM4 as a novel cancer stem cell-associated molecule and potential target in triple negative breast cancer 64
Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure 62
PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas 61
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients. 61
The role of molecular analysis in breast cancer. 58
Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes 57
Neoplastic cell percentage estimation in tissue samples for molecular oncology: recommendations from a modified Delphi study 57
Inclusion of platinum agents in neoadjuvant chemotherapy regimens for triple-negative breast cancer patients: Development of GRADE (grades of recommendation, assessment, development and evaluation) recommendation by the Italian association of medical oncology (AIOM) 56
Reccomendations for using of molecular assays on liquid biopsy: The first document provided by intersociety Group AIOM, SIF, SIAPEC-IAP, SIBioC 56
CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. 55
Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas). 55
Chemotherapy with or without trastuzumab. 55
Tiling path genomic profiling of grade 3 invasive ductal breast cancers. 55
Optimized EGFR blockade strategies in EGFR addicted gastroesophageal adenocarcinomas 53
Well-differentiated neuroendocrine tumour of the breast showing peculiar endovascular spread. 52
RNASeq analysis reveals biological processes governing the clinical behaviour of endometrioid and serous endometrial cancers 52
Loss of 16q in high grade breast cancer is associated with estrogen receptor status: Evidence for progression in tumors with a luminal phenotype? 50
Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma 50
The pathologic complete response open question in primary therapy 49
Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment. 49
Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. 48
Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast 48
Genomic and immunophenotypical characterization of pure micropapillary carcinomas of the breast 47
AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells 47
Breast Cancer Heterogeneity: Roles in Tumorigenesis and Therapeutic Implications 46
Myxoid renal tumor with myoepithelial differentiation mimicking a salivary gland pleomorphic adenoma: description of a case 46
The genomic profile of HER2-amplified breast cancers: the influence of ER status 46
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis 45
Gene Status in HER2 Equivocal Breast Carcinomas: Impact of Distinct Recommendations and Contribution of a Polymerase Chain Reaction-Based Method. 45
Tissues under-vacuum to overcome suboptimal preservation 45
Reoperation rate after breast conserving surgery as quality indicator in breast cancer treatment: A reappraisal 45
ESR1 amplification in endometrial carcinomas: hope or hyperbole? 43
Hereditary breast cancer: from molecular pathology to tailored therapies. 43
Totale 10358
Categoria #
all - tutte 18551
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18551


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/2018785 0000 00 0144 3751525262
2018/20191353 50294967 9158 62172 61137389188
2019/20202470 127122113289 182383 260229 320171152122
2020/20211962 103134139126 142160 202102 194216148296
2021/20222108 101124156208 12895 133148 84167398366
2022/20231864 26717571196 257632 2606 0000
Totale 11795